Damora Therapeutics, Inc. cash flow to debt ratio of -9.89K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Damora Therapeutics, Inc.'s free cash flow has increased -63.88% from $-18.62M last year to $-6.73M, signaling increasing performance

Damora Therapeutics, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Damora Therapeutics, Inc.'s debt has decreased relative to shareholder equity from 0.10 last year to 0.00 today, signaling strengthened financials

Damora Therapeutics, Inc. has a net cash position, so leverage is healthy.

Damora Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Damora Therapeutics, Inc. has insufficient data to evaluate this check.

Damora Therapeutics, Inc.'s short-term assets of $260.42M exceed its short-term liabilities of $20.07M

Damora Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Damora Therapeutics, Inc.'s return on equity of -122.61%, is lower than 15.00%, indicating bad performance

Damora Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Damora Therapeutics, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Damora Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Damora Therapeutics, Inc. has negative free cash flow, indicating cash burn

Damora Therapeutics, Inc.'s yearly earnings has decreased 878.77% since last year from $-21.44M to $-209.84M, signaling decreasing performance

Damora Therapeutics, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -46.73% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Damora Therapeutics, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Damora Therapeutics, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Damora Therapeutics, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Damora Therapeutics, Inc. has insufficient data to evaluate this check.

Damora Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Damora Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Damora Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Damora Therapeutics, Inc. has insufficient data to evaluate this check.

Damora Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Damora Therapeutics, Inc. has a price-to-book ratio of 1.99x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Damora Therapeutics, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue